The B6-hALK7 (hACVR1C) mouse is a humanized model constructed using gene editing technology, where the region from aa.27 in exon 2 to partial intron 2 of mouse Acvr1c was replaced with "ACVR1C chimeric CDS-WPRE-BGH pA" cassette. The murine signal peptide (aa.1~25) of Acvr1c was preserved. This model can be used for studying the pathological mechanisms and therapeutic approaches of metabolic disorders such as obesity and type 2 diabetes, and certain cancers like retinoblastoma, and for the development of ACVR1C-targeted drugs.

The B6-hDPP4 (line 2) mouse is a humanized model constructed by gene editing technology to replace a partial region of the mouse Dpp4 gene with the human DPP4 gene CDS sequence. This model can be used to study the infection mechanisms of viruses such as MERS-CoV and COVID-19, as well as to develop related virus vaccines. Additionally, this model can be utilized to develop DPP4 inhibitor therapies. Similar models include the B6-hDPP4(line 1) mouse (Catalog ID: I001187), constructed on the C57BL/6NCya background strain, which replaces the sequence encoding aa.29~aa.760 of the mouse Dpp4 gene with the human DPP4 gene CDS sequence (aa.29-766), and the BALB/c-hDPP4 (line 2) mouse (Catalog ID: I001189), constructed on the BALB/cAnCya background strain. These models meet the experimental needs of different strain backgrounds.

The B6-hDPP4 (line 1) mouse is a humanized model constructed by gene editing technology to replace a partial region of the mouse Dpp4 gene with the human DPP4 gene CDS sequence. This model can be used to study the infection mechanisms of viruses such as MERS-CoV and COVID-19, as well as to develop related virus vaccines. Additionally, this model can be utilized to develop DPP4 inhibitor therapies. Additionally, Cyagen Biosciences has developed B6-hDPP4(line 2) mice (Catalog ID: I001188) on the C57BL/6JCya background strain and BALB/c-hDPP4 (line 2) mice (Catalog ID: I001189) on the BALB/cAnCya background strain. These two models replace the mouse Dpp4 gene p.S29 to part of intron 2 with the Human DPP4 CDS (aa.29-766)-rBG pA expression cassette, meeting the experimental needs for different strain backgrounds.

B6-hFGF21 mice are humanized models generated by replacing the sequence of the mouse Fgf21 gene in situ with the corresponding sequence from the human FGF21 gene. This model can be used to study the pathological mechanisms and therapeutic methods of metabolic diseases such as obesity, diabetes, and metabolic associated steatohepatitis (MASH), cardiovascular diseases, cancers, as well as the screening and development of FGF21-targeted drugs, and preclinical efficacy and safety evaluations.

B6-hFGFR1c mice are humanized models generated by gene editing technology, in which the p.22R to partial intron 2 of the mouse Fgfr1 gene was replaced in situ with p.22R to 376E from the coding sequence of the human FGFR1 gene, p.377I to 823X from the coding sequence of the mouse Fgfr1 gene, and the 3'UTR of the mouse Fgfr1 gene. This model can be used to study the pathological mechanisms and therapeutic methods of cancers, metabolic diseases such as obesity, diabetes, and metabolic-associated steatohepatitis (MASH), as well as the screening and development of FGFR1c-targeted drugs, and preclinical efficacy and safety evaluations.

The B6-hGCGR mouse is a humanized model constructed by replacing the sequence of the mouse Gcgr gene in situ with the corresponding sequence from the human GCGR gene. The B6-hGCGR mice can be used for studies on obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and other glucose-related metabolic disorders, as well as for GCGR-targeted drug development.

This strain is a mouse Gdf15 gene humanized model expressing human GDF15 protein obtained by replacing the sequence encoding the endogenous structural domain in the mouse Gdf15 gene with the sequence encoding the structural domain in the human GDF15 gene. B6-hGDF15 mice can be used for research on metabolic diseases, cardiovascular diseases, tumor occurrence and development, etc., to assist in the preclinical evaluation of GDF15-targeted drugs.

The B6-hGIPR/hGLP-1R mouse is a dual humanized model for Gipr and Glp1r genes. Using gene-editing technology, a partial coding sequence (CDS) of the human GIPR gene was inserted into the mouse Gipr gene sequence in B6-hGLP-1R mice (Catalog No.: C001421). This model expresses the functional region of the human GIPR protein while preserving the mouse signal peptide. It can be used to study the pathogenic mechanisms of metabolic diseases such as obesity and type 2 diabetes, and the development of GIPR/GLP-1R dual agonist drugs. The homozygotes are viable and fertile.

B6-hGLP-1R mice is a model of mouse Glp1r gene humanization, in which the sequences encoding the seven-transmembrane (7TM) structural domain and the larger extracellular structural domain of the human GLP1R gene were inserted into the mouse Glp1r gene sequence using gene editing technology. This model expresses the key functional regions of the human GLP-1R protein while preserving the signal peptide and 3’UTR region of mouse GLp1r. It can be used to study the pathogenesis of various metabolic diseases such as obesity and type II diabetes, as well as for screening in GLP-1RA drug development. Homozygous B6-hGLP-1R mice are viable and fertile.

The B6-hGLP-1R/ob mouse model, generated by mating B6-hGLP-1R mice (Catalog Number: C001421) with Lep KO (ob/ob) mice (Catalog Number: C001368), is a metabolic disease model. It can be used for research on the pathogenic mechanisms of various metabolic diseases, such as obesity and type II diabetes, and for screening GLP-1RA drugs.